• January 2010
Imaging3 Hosts Conference Call Regarding FDA Status
Burbank, CA – January 12, 2010 – Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, conducted a Conference Call on Tuesday, January 12, 2010 at 1:00 Pacific Standard Time. During the call, CEO Dean Janes discussed the company’s recent response from the FDA. The announcement was followed by a question and answer session in which Mr. Janes took questions.
The audio recording of the conference call is now available on the company’s website.
About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information.
Contact:
Imaging3, Inc.
Mike Nessen
800-900-9729
Mike@imaging3.com
Media Contact:
Lorena Meza
LM Public Relations
310-560-8927
lmeza@lmpublicrelations.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
